MarketCap
Verrica Pharmaceuticals VRCA
$ 3.4
-14.14%
Facebook
X
Telegram
Verrica Pharmaceuticals Operating Expenses | VRCA
Annual Operating Expenses Verrica Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.8 M | 73.5 M | 70.9 M | 30.3 M | 42.9 M | 40.2 M | 30.1 M | 21.9 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.5 M | 21.9 M | 44.7 M |
Quarterly Operating Expenses Verrica Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 M | 14.7 M | 12.7 M | 11.2 M | 11.6 M | - | 18.9 M | 20.4 M | 22.4 M | - | 26.8 M | 11.8 M | 7.13 M | - | 6.87 M | 9.34 M | 7.84 M | - | 11.8 M | 10.7 M | 11.9 M | - | 9.64 M | 8.63 M | 9.88 M | 7.99 M | 6.54 M | 7.52 M | 8.03 M | 8.19 M | 6.33 M | 5.47 M | 1.89 M | 1.43 M | 1.36 M | 1.1 M | 570 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.8 M | 570 K | 9.99 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Vir Biotechnology
VIR
|
186 M | $ 11.02 | 4.27 % | $ 1.53 B |  USA |
 |
Viking Therapeutics
VKTX
|
393 M | $ 24.23 | -0.72 % | $ 2.73 B | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
98.4 M | - | - | $ 384 M |  Britain |
 |
Cabaletta Bio
CABA
|
172 M | $ 1.34 | -9.18 % | $ 135 M | USA |
 |
CytomX Therapeutics
CTMX
|
98.6 M | $ 2.23 | -4.09 % | $ 308 M | USA |
 |
Vanda Pharmaceuticals
VNDA
|
180 M | $ 3.95 | -1.62 % | $ 233 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
19.3 M | - | - | $ 717 K | USA |
 |
Viridian Therapeutics
VRDN
|
434 M | $ 23.31 | 4.2 % | $ 2.37 B | USA |
 |
G1 Therapeutics
GTHX
|
122 M | - | - | $ 370 M | USA |
 |
Verastem
VSTM
|
147 M | $ 9.9 | -1.34 % | $ 686 M | USA |
 |
VistaGen Therapeutics
VTGN
|
73.4 M | $ 0.17 | -3.9 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
172 M | $ 1.76 | 0.86 % | $ 103 M | USA |
 |
Amryt Pharma plc
AMYT
|
109 M | - | - | $ 621 M | Britain |
 |
Kinnate Biopharma
KNTE
|
121 M | - | - | $ 123 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
447 M | - | - | $ 7.29 B | USA |
 |
NexImmune
NEXI
|
33 M | - | 70.13 % | $ 4.12 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
258 M | $ 3.23 | -0.16 % | $ 545 M |  Singapore |
 |
Theravance Biopharma
TBPH
|
25.9 M | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Xenetic Biosciences
XBIO
|
5.81 M | $ 1.72 | 3.78 % | $ 2.93 M | USA |
|
XBiotech
XBIT
|
42.5 M | $ 1.82 | -5.7 % | $ 55.5 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
381 M | $ 35.76 | 1.19 % | $ 2.83 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
94.7 M | $ 10.21 | 0.05 % | $ 1.64 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
108 M | $ 3.26 | 0.46 % | $ 138 M | USA |
 |
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | Canada |
 |
22nd Century Group
XXII
|
8.43 M | $ 0.09 | -54.43 % | $ 16.6 K | USA |
 |
Karuna Therapeutics
KRTX
|
495 M | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
96.8 M | - | - | $ 756 M | USA |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
LogicBio Therapeutics
LOGC
|
44.4 M | - | - | $ 229 M | USA |
 |
Zai Lab Limited
ZLAB
|
212 M | $ 24.36 | 1.35 % | $ 26.7 B |  China |
|
89bio
ETNB
|
385 M | - | - | $ 1.55 B | USA |
 |
Zentalis Pharmaceuticals
ZNTL
|
153 M | $ 2.06 | -6.79 % | $ 148 M | USA |
 |
Zymeworks
ZYME
|
53.2 M | $ 28.38 | 0.57 % | $ 1.46 B | Canada |
 |
Fusion Pharmaceuticals
FUSN
|
101 M | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
156 M | - | 0.42 % | $ 213 M | USA |
 |
Harpoon Therapeutics
HARP
|
100 M | - | - | $ 763 M | USA |
 |
HOOKIPA Pharma
HOOK
|
56.3 M | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
9.73 M | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
42.6 M | - | - | $ 109 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
42.6 M | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
Seagen
SGEN
|
1.09 B | - | - | $ 42.2 B | USA |
 |
Baudax Bio
BXRX
|
54.6 M | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
33 K | - | 7.23 % | $ 2.72 M | USA |